You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行报告》瑞信上调锦欣生殖(01951.HK)目标价至13.54元 评级「跑赢大市」
阿思达克 07-02 11:54
瑞信发表研究报告指,锦欣生殖(01951.HK)日前斥资3.15亿元人民币收购武汉黄浦医院75%股权,认为交易条件吸引,公司可藉此进军辅助生育(IVF)服务渗透率较低、市场分散的湖北地区。

报告指出,武汉黄浦医院在末来3年将每年可进行3,000个IVF治疗周期,并预期於2022年达到收支平衡,净利润率维持20%。该行指,锦欣生殖收购武汉黄浦医院後,将斥资6,000万至7,000万元人民币翻新该医院,预期每年可进行IVF治疗周期将增至6,000多个,料於今年至2023年为公司贡献2,300万至1.37亿元人民币收入。

该行续指,收购为公司提供长期增长机会,加上其行业领先地位,维持「跑赢大市」评级,目标价由12元升至13.54元,但将2021至2022财年盈利预测下调5.8%及5.3%。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account